Allogeneic gamma delta T cell therapies

Search documents
Adicet Bio, Inc. Announces $80 Million Registered Direct Offering
Businesswireยท 2025-10-07 11:01
Core Viewpoint - Adicet Bio, Inc. has announced a registered direct offering of 70,001,000 shares of its common stock, along with pre-funded warrants for an additional 10,000,000 shares, indicating a significant capital raise to support its clinical stage biotechnology initiatives [1] Company Summary - Adicet Bio, Inc. is a clinical stage biotechnology company focused on discovering and developing allogeneic gamma delta T cell therapies aimed at treating autoimmune diseases and cancer [1]